The Endpoints 11 awards are our chance to tell a story about where biotech is going. In some ways, biotech feels like it has finally emerged from years of uncertainty. The money that fuels the industry has returned to public and private markets. And it's driven by fundamentals, rather than pandemic-era narrative. But in other ways, the industry's future is more uncertain than ever. There's been a shift in biopharma's traditional power structures, with rising influence from AI, China and a new class of companies that might just become the next big players. This year's list of 11 startups helps tell that story. We received more than 150 nominations — from industry leaders, marquee investors and at least one Nobel Prize winner — and sourced many more companies on our own. Since late spring, Endpoints News journalists have have spent dozens of hours researching candidates and debating who deserved to make the cut. The 11 companies on our list include startups pursuing new approaches in gene therapy, CAR-T, oncology and cardiology, as well as companies working in longevity, AI and robotics, and novel ideas for drug development. Here is the 2026 Endpoints 11 — the startups making the most interesting bets in biotech: Anew Labs: A China-based rival to AI labs Azalea Therapeutics: Melding gene editing and CAR-T Corsera Health: Maraganore and Meanwell’s next big bet in cardiology K2 Therapeutics: Marrying China’s speed with global expertise Kali Therapeutics: Turning from China to an in-house pipeline Medici Therapeutics: A science super-team bets the future of cancer therapy is personalized Medra: Building self-driving labs that change how scientists work NewLimit: Looking beyond Yamanaka factors for a new class of anti-aging medicines SonoThera: A bold new approach to nonviral gene therapy Stipple Bio: Taking precision oncology to the next level Vivodyne: A human tissue factory could change how drugs are tested Our winners were unveiled last night at our gala event in Boston.